Henderson Morley
Trending Articles
Related Content
Research & Development
Second firm shows interest in ICVT portfolio
UK biotechnology firm Henderson Morley has received a letter of intent (LOI), from an unnamed specialist therapeutic drug development company relating to the intellectual property rights (IPR) of its ICVT portfolio, specifically the recurrent respiratory papilloma (RRP) indication.